Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Chimeric Antigen Receptor T-cell (CAR-T) therapy is a potent cellular immune treatment that genetically trains an individual’s immune system (specifically, the T-cells, a type of white blood cell) to both recognize and attack cancerous cells.
Chimeric antigen receptor T-cell (CAR-T) therapy can provide durable remissions in a subset of patients with Richter’s transformation.
Chimeric antigen receptor T-cell (CAR-T) therapy can provide durable remissions in a subset of patients with Richter’s transformation.
This research shows that senescence (biological aging) can occur in CAR-T cells, reducing their ability to kill cancer cells.
and President, interviewed Dr. Alexey Danilov, Associate Director of the Toni Stephenson Lymphoma Center at City of Hope in Duarte, CA. They discussed the development of Richter transformation after chimeric antigen receptor T-cell (CAR-T) therapy.
CAR-T therapy is a revolutionary therapy that trains the patient’s own cells to attack their CLL / SLL. The science can be somewhat complicated and advanced, but the results can be amazing. You
ASH 2019: Dr. David Maloney on CAR-T therapy in CLL (chronic lymphocytic leukemia)
CAR-T is a revolutionary therapy in CLL and other blood cancers. As part of the team led by Dr. Carl June at U. Penn, Dr. Joe Fraietta’s translational research has taken CAR-T from an exciting possibility to a lifesaving “living drug”. Don’t miss this opportunity to be able to learn about the latest CAR-T research and to ask your questions of one of CAR-T’s most innovative pioneers.
iwCLL 2019: Dr. David Maloney on targeted agents, transplants, and CAR-T therapy for treating chronic lymphocytic leukemia (CLL)
One click to our most popular content.
